Switch to:
Also traded in: Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 39.17
KMDA's Cash to Debt is ranked lower than
52% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 56.57 vs. KMDA: 39.17 )
Ranked among companies with meaningful Cash to Debt only.
KMDA' s Cash to Debt Range Over the Past 10 Years
Min: 1.32  Med: 5.54 Max: N/A
Current: 39.17
Equity to Asset 0.67
KMDA's Equity to Asset is ranked lower than
52% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. KMDA: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
KMDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.64 Max: 0.71
Current: 0.67
0.28
0.71
F-Score: 4
Z-Score: 1.99
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -10.10
KMDA's Operating margin (%) is ranked higher than
66% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. KMDA: -10.10 )
Ranked among companies with meaningful Operating margin (%) only.
KMDA' s Operating margin (%) Range Over the Past 10 Years
Min: -121.42  Med: -16.15 Max: 5.83
Current: -10.1
-121.42
5.83
Net-margin (%) -10.92
KMDA's Net-margin (%) is ranked higher than
65% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. KMDA: -10.92 )
Ranked among companies with meaningful Net-margin (%) only.
KMDA' s Net-margin (%) Range Over the Past 10 Years
Min: -170.4  Med: -18.59 Max: 0.63
Current: -10.92
-170.4
0.63
ROE (%) -11.32
KMDA's ROE (%) is ranked higher than
66% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -31.69 vs. KMDA: -11.32 )
Ranked among companies with meaningful ROE (%) only.
KMDA' s ROE (%) Range Over the Past 10 Years
Min: -196.96  Med: -20.08 Max: 1.83
Current: -11.32
-196.96
1.83
ROA (%) -7.68
KMDA's ROA (%) is ranked higher than
68% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. KMDA: -7.68 )
Ranked among companies with meaningful ROA (%) only.
KMDA' s ROA (%) Range Over the Past 10 Years
Min: -59.2  Med: -11.02 Max: 0.58
Current: -7.68
-59.2
0.58
ROC (Joel Greenblatt) (%) -16.05
KMDA's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. KMDA: -16.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KMDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -111.83  Med: -13.79 Max: 26.43
Current: -16.05
-111.83
26.43
Revenue Growth (3Y)(%) -2.70
KMDA's Revenue Growth (3Y)(%) is ranked lower than
56% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. KMDA: -2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KMDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.7  Med: 25.35 Max: 44.1
Current: -2.7
-2.7
44.1
EPS Growth (3Y)(%) 39.60
KMDA's EPS Growth (3Y)(%) is ranked higher than
88% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. KMDA: 39.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KMDA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -60.30 Max: 39.6
Current: 39.6
-100
39.6
» KMDA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

KMDA Guru Trades in Q2 2015

Jim Simons 204,400 sh (+20.88%)
John Paulson 739,356 sh (unchged)
» More
Q3 2015

KMDA Guru Trades in Q3 2015

John Paulson 739,356 sh (unchged)
Jim Simons 156,500 sh (-23.43%)
» More
Q4 2015

KMDA Guru Trades in Q4 2015

Jim Simons 166,300 sh (+6.26%)
John Paulson 739,356 sh (unchged)
» More
Q1 2016

KMDA Guru Trades in Q1 2016

Jim Simons 170,300 sh (+2.41%)
John Paulson 736,117 sh (-0.44%)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XKRX:046210, NAS:TTNP, NAS:FBIO, TSE:2370, XTAE:RDHL, TPE:1734 » details
Traded in other countries:KMDA.Israel,
Kamada Ltd is an orphan drug, plasma-derived protein Therapeutics Company and develops & produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.

Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.

Ratios

vs
industry
vs
history
Forward P/E 370.37
KMDA's Forward P/E is ranked lower than
99% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 19.05 vs. KMDA: 370.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.90
KMDA's P/B is ranked higher than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 3.51 vs. KMDA: 1.90 )
Ranked among companies with meaningful P/B only.
KMDA' s P/B Range Over the Past 10 Years
Min: 1.47  Med: 2.81 Max: 11.39
Current: 1.9
1.47
11.39
P/S 1.76
KMDA's P/S is ranked higher than
90% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. KMDA: 1.76 )
Ranked among companies with meaningful P/S only.
KMDA' s P/S Range Over the Past 10 Years
Min: 1.6  Med: 3.44 Max: 15.18
Current: 1.76
1.6
15.18
Current Ratio 3.11
KMDA's Current Ratio is ranked lower than
63% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. KMDA: 3.11 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.19 Max: 4.42
Current: 3.11
2.21
4.42
Quick Ratio 1.95
KMDA's Quick Ratio is ranked lower than
71% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. KMDA: 1.95 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.32 Max: 3.59
Current: 1.95
1.45
3.59
Days Inventory 179.87
KMDA's Days Inventory is ranked lower than
66% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. KMDA: 179.87 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s Days Inventory Range Over the Past 10 Years
Min: 34.72  Med: 125.92 Max: 187.18
Current: 179.87
34.72
187.18
Days Sales Outstanding 86.53
KMDA's Days Sales Outstanding is ranked lower than
66% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. KMDA: 86.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 69.61  Med: 89.95 Max: 97.76
Current: 86.53
69.61
97.76
Days Payable 148.71
KMDA's Days Payable is ranked higher than
78% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. KMDA: 148.71 )
Ranked among companies with meaningful Days Payable only.
KMDA' s Days Payable Range Over the Past 10 Years
Min: 89.24  Med: 116.34 Max: 138.19
Current: 148.71
89.24
138.19

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.73
KMDA's Price/Net Current Asset Value is ranked higher than
76% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 5.18 vs. KMDA: 2.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KMDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.31  Med: 3.82 Max: 38.53
Current: 2.73
2.31
38.53
Price/Tangible Book 1.90
KMDA's Price/Tangible Book is ranked higher than
80% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. KMDA: 1.90 )
Ranked among companies with meaningful Price/Tangible Book only.
KMDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.68  Med: 2.79 Max: 10.06
Current: 1.9
1.68
10.06
Price/Median PS Value 0.49
KMDA's Price/Median PS Value is ranked higher than
82% of the 679 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. KMDA: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
KMDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1.01 Max: 4.25
Current: 0.49
0.5
4.25
Earnings Yield (Greenblatt) (%) -7.30
KMDA's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: -9.20 vs. KMDA: -7.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KMDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.00 Max: 2.7
Current: -7.3
0.1
2.7

More Statistics

Revenue (TTM) (Mil) $75.77
EPS (TTM) $ -0.22
Beta1.06
Short Percentage of Float0.02%
52-Week Range $3.09 - 4.67
Shares Outstanding (Mil)36.42

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 329 385 416
EPS ($) -0.38 0.04 1.90
EPS without NRI ($) -0.38 0.04 1.90
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
Kamada’s Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early... May 25 2016
Kamada’s Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early... May 25 2016
Kamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016
Kamada Reports 2016 First Quarter Financial Results May 09 2016
Kamada reports 1Q loss May 09 2016
Kamada reports 1Q loss May 09 2016
Kamada Reports 2016 First Quarter Financial Results May 09 2016
Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern... May 04 2016
Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern... May 04 2016
Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and... May 03 2016
Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and... May 02 2016
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the... Apr 07 2016
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the... Apr 06 2016
Kamada Submits Marketing Authorization Application with the European Medicines Agency for its... Mar 28 2016
KAMADA LTD Financials Mar 04 2016
Kamada Ltd. Earnings Analysis: 2015 By the Numbers Feb 05 2016
Kamada to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference Feb 05 2016
New Strong Buy Stocks for February 4th Feb 04 2016
Kamada posts 4Q profit Feb 02 2016
Kamada posts 4Q profit Feb 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)